-
On the importance of human connection
There is power in connection. As humans, we all learn this truth at a young […]
-
Update to the U.S. Duchenne Community on the Ataluren (Translarna) for Nonsense Mutation Duchenne Muscular Dystrophy
The FDA is continuing its review of Ataluren (Translarna), the first potential therapy specifically for […]
-
In Case You Missed It…
Quest Media is an innovative adaptive lifestyle platform from MDA. With the power of this […]
-
Entrada Therapeutics doses first participant in Exon 44 skipping program; provides updates to other exon-skipping programs
Entrada Therapeutics, which received early funding from CureDuchenne, has provided updates on the status of […]
-
Disabled artists’ challenges can propel creative solutions
As an artist with Duchenne muscular dystrophy (DMD), I’ve long recognized how creativity can foster […]
-
FSHD patients sought for first clinical trial testing EPI-321
Enrollment is now ongoing in a first-in-human trial testing EPI-321, an epigenetic therapy designed to […]
-
DYNE-251 for DMD granted FDA breakthrough therapy designation
The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to Dyne Therapeutics’ […]
-
Behind the Drug: Nusinersen (Spinraza) for SMA
Spinal muscular atrophy (SMA) is a rare genetic disease that affects the peripheral nervous system […]
-
Dyne Therapeutics granted Breakthrough Therapy Designation for exon-51skipping therapeutic, DYNE-251
CureDuchenne was an early investor in Dyne Therapeutics in 2020, and congratulates the company for receiving Breakthrough Therapy […]
-
Dyne Therapeutics, Inc. announced today FDA Breakthrough Therapy Designation for DYNE-251 in Duchenne Muscular Dystrophy
Dyne Therapeutics has announced FDA Breakthrough Therapy Designation for DYNE-251 in Duchenne Muscular Dystrophy. This […]
